A Summary of Recent Advances in Ocular Inserts and Implants

With the physiological and anatomical constraints put forth by the eye it is a significant challenge to the pharmaceutical scientists to target drugs to the posterior segment of the eye. Severe ocular complications such as glaucoma, uveitis, cytomegalovirus retinitis, cataracts, age related macular degeneration, diabetic retinopathy, and retinitis pigmentosa pose urgency for the treatment of ocular diseases. Hence novel drug delivery strategies and formulations are to be developed and explored to overcome and treat these posterior ocular disorders. At present the topical and intravitreal routes are widely used to deliver therapeutic entities to retinal tissue. Various controlled delivery systems, such as ocular inserts and implants are in the progress of development and may improve drug delivery drastically in the years to come. In this review, we discuss the recent developments in ocular delivery using ocular implants and inserts. *Corresponding author: Lynda Paul Jervis, Pharmaceutical Sciences, Fairleigh Dickinson University, 1000 River Road, Teaneck, NJ, USA, Tel: 609-738-7000; Fax: 973 443-8795; E-mail: [email protected] Received November 30, 2016; Accepted December 16, 2016; Published January 02, 2017 Citation: Jervis LP (2017) A Summary of Recent Advances in Ocular Inserts and Implants. J Bioequiv Availab 9: 320-323. doi: 10.4172/jbb.1000318 Copyright: © 2017 Jervis LP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Jervis LP (2017) A Summary of Recent Advances in Ocular Inserts and Implants. J Bioequiv Availab 9: 320-323. doi: 10.4172/jbb.1000318 J Bioequiv Availab, an open access journal ISSN: 0975-0851 Volume 9(1): 320-323 (2017) 321 Implants Recent technological advances in the field of biomedical engineering and ocular surgery fortified the insight of design and development of sustained-release drug delivery implants for the treatment of various clinical ophthalmic complications [23,24]. Sustained release ocular implants are the drug delivery devices for sustained release of molecules from either biodegradable or non-biodegradable polymeric matrices over several months to years. The foremost intraocular implants were developed in order to achieve controlled and sustained drug delivery to treat long term ophthalmic disorders. These devices can be implanted in subconjuctival, episcleral, intravitreal, intracameral regions. Biodegradable solid implants are fabricated using Polylactic Acid (PLA), Polyglycolic Acid (PGA), and Polylactic-co-Glycolic Acid (PLGA) Polycaprolactones (PCL) polyanhydrides which does not need post treatment surgical removal unlike non-biodegradable implants, but can cause erratic drug release profiles [25]. Kochinke et al. patented the fabrication of dexamethasone monolithic ocular implant using polyester of lactic and glycolic acid with hydroxypropyl methyl cellulose which could deliver drug for the period of 3 days. This implant can be inserted into various sites of the eye depending up on the ailment and condition to be treated [26,27]. Non-biodegradable implants are made up of polyvinyl alcohol (PVA)-Ethylene Vinyl Acetate (EVA), Polysulfone Capillary Fiber (PCF). Rahimy et al. conducted studies to investigate PCF as drug delivery device for intraocular applications. Carboxyfluorescein (CF) was used as the model drug for these studies and the subsequent release kinetics of CF from the PCF device was monitored in vivo in the rabbit’s eye. PCF dye device was implanted in the vitreous cavity, and fluorophotometry from the retina to the anterior chamber was performed at various times up to 45 days to quantify fluorescein level. At the conclusion of the study, eyes were enucleated and examined for histopathology. The time-course study showed fluorescein level for up to 45 days in the vitreous and further histological examination of the eyes implanted with PCF or PCF-dye device showed no sign of ocular toxicity. Overall, these results may imply that the PCF device is biocompatible and may be useful for the extended release of drugs in the posterior segment of the eye [28-30]. Kim et al. attempted to Deliver Gadolinium-Pentetic Acid (Gd-DTPA) to the posterior segment by episcleral sustained release implant and the release rate of the episcleral implant was compared with intravitreal implant (in vivo). Episcleral implants delivered 2.7 μg in to the vitreous cavity comprising only 0.12% of the drug in the implant and there were no significant amounts of the drug in the posterior chamber. Intravitreal implants delivered the drug in to the vitreous humour and posterior segments of the eye. The concentration of the drug in the vitreous was 30 times higher (ex vivo) when compared to episcleral implant. Author hypothesized that three-dimensional MRI and the data would be useful to study the ocular disposition mechanisms in the eye [31]. In other study Kim YM et.al delivered the triamcinolone acetonide into posterior segment of the eye using the intrascleral implant. The implant was made of poly (D,L-lactide) comprising 6.4 mg of Triamcinolone Acetonide (TA). Sustained release of triamcinolone acetonide for 90 days was observed in the in vitro studies and a significant level of TA in aqueous humor until 4 weeks was detected and in retina-choroid until 8 weeks after implantation, but in the vitreous cavity TA was found over 12 weeks. There were no signs of retinal detachment or toxicity in the in vivo studies [32]. Gwon and Meadows patented the subconjunctival implants of pilocarpine which could significantly deliver and control the release of drugs into the ocular posterior segment. The implants are made of ethylene vinyl acetate polymer which controls the release of drug; amount of drug disposed into conjunctiva can be determined by fluorescent tracer embedded in the subconjunctival implant [33]. Okaba et al. prepared and evaluated biodegradable scleral implant for the sustained release of steroid betamethasone phosphate to the posterior segments of the eye (in vitro). The implant with dimensions of 0.5 mm thick and 4mm in diameter made up of poly (DL-lactide) was inserted in to scleral pocket of the rabbit’s eye. The drug levels in the posterior tissues like vitreous and Retina-Choroid (RC) was maintained constant for 8 weeks. The drug concentration in the RC was significantly greater than in the vitreous humor. Drug levels in the aqueous humor were below limit of detection. The implant exerted good compatibility in eye and there was no significant toxicity to the retina during the experimental studies [34,35]. Michelson and Nozik fabricated implantable osmotic mini pump device, which was inserted subcutaneously in the ear region of a rabbit model of endophthalmitis. The device had connective tubing directly infusing into the vitreous cavity through a pars plana incision and maintained a calculated dose of the antibiotic gentamicin (0.01 mg/h) over 4 days [36]. Silvia et.al formulated dexamethasone intravitreal implants made up of polymer poly(ɛ-caprolactone) which is suitable for the long term sustained release drug delivery to the vitreous humor. Characteristics of the poly (ɛ-caprolactone) device, feasibility and intravitreal release of dexamethasone were extensively studied in this experiment. In vitro release of dexamethasone was determined and interaction between the drug and the polymer was evaluated by the differential scanning colorimetry. Poly(ɛ-caprolactone) device provided the sustained release of dexamethasone since it releases 25% of the drug loaded in 21 weeks. There were no significant changes during the experimental studies with morphology, toxicity, and other biological characteristics [37,38]. Carcaboso et al. attempted to deliver topotecan to the posterior segment of the eye for the treatment of intraocular retinoblastoma. Episcleral Implant was developed to control and sustain the delivery of topotecan in to the posterior segment. Implants released 30% to 50% of the drug within 48 hours and 45% to 70% by 10th day (in vitro). In vivo, topotecan lactone was highly accumulated in ocular tissues such as (sclera, choroid, retina) over 48 hours with all the formulations studied. Low vitreous topotecan lactone levels were detected with high drug load implants [39]. Ganciclovir loaded biodegradable donut shaped minitablet was developed by Choonara et al. for the treatment of human cytomegalovirus retinitis. Specialised tablet tooling equipment was used to manufacture the device composed of polylactic-co-glycolic acid. Device was implanted through parsplana/peripheral retina of rabbits and the left eyes were used as control. The minitablet was well tolerated up to 72 days in super temporal quadrant of the eye. The device exhibited the control release of ganciclovir at the constant rate of 2.02 μg/h throughout the experimental studies [40]. Current Marketed Products